Results 61 to 70 of about 66,588 (284)

Bisphosphonate-induced periprosthetic fracture: a cause of painful total hip arthroplasty [PDF]

, 2014
Background. Cases have been reported in the literature of periprosthetic fractures associated with the use of bisphosphonates occurring in the long term following a Total Hip Replacement (THR).
Bhattacharyya, Rahul, O’Neill, Gavin, Periasamy, Kumar, Spence, Stephanie   +3 more
core   +4 more sources

Affinity‐Based Interactome Mapping of Inositol Pyrophosphates Reveals 4/6‐PP‐InsP5‐Binding Proteins in Plants

Advanced Science, EarlyView.
ABSTRACT Inositol pyrophosphates (PP‐InsPs) are central regulators of eukaryotic signaling events. While certain PP‐InsP isomers have been conclusively linked to the regulation of phosphate homeostasis through interaction with SPX domain‐containing proteins in plants, the functions of the recently discovered isomer 4/6‐PP‐InsP5 remain largely unknown ...
Kevin Ritter, Verena Gaugler, Sara Christina Stolze, Riya Ghosh, Akhila Jayamon, Ranjana Yadav, Felix Wollensack, Debabrata Laha, Hirofumi Nakagami, Gabriel Schaaf, Henning Jacob Jessen   +10 more
wiley   +1 more source

The survey of anti-inflammatory effect of bisphosphonates

Journal of Mazandaran University of Medical Sciences, 2009
(Received 13 Dec, 2008 ; Accepted 28 Jan, 2009)AbstractBisphosphonates are currently used in metabolic disorder of bone; however, there have been few studies that reviewed the role of anti-inflammatory and immune modulatory effect of this agent in in ...
Reza Shiari, Mohammad Mehdi Nasehi, Shervin Farivar, Bijan Hatamian   +3 more
doaj  

Bisphosphonates: An update

Journal of Pharmacy and Bioallied Sciences, 2012
Bisphosphonates are used widely for variety of bone condition, most notably IV bisphosphonates in the treatment of metastic bone lesion and oral bisphosphonates for osteoporosis.
Nalliappan Ganapathy, Subramanium Gokulnathan, Nataraj Balan, Thangadurai Maheswaran, Venkatesan   +4 more
doaj   +1 more source

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

BMC Musculoskeletal Disorders, 2022
Background Both denosumab and bisphosphonates have been demonstrated effective for glucocorticoid-induced osteoporosis. However, evidence-based medicine is still lacking to prove the clinical results between denosumab and bisphosphonates.
Lianghai Jiang, Jian Dong, Jianwei Wei, Lantao Liu   +3 more
doaj   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis

BMC Musculoskeletal Disorders, 2007
Background It is still unclear whether addition of calcium/vitamin D supplements leads to an incremental benefit in patients taking bisphosphonates and whether achievement of serum level of 25 (OH) vitamin D of at least 70 nmol/L has an impact on the ...
Fogelman Ignac, Constancio Leonor, Deane Andrew, Hampson Geeta   +3 more
doaj   +1 more source

Bisphosphonate's and Intermittent Parathyroid Hormone's Effect on Human Spinal Fusion: A Systematic Review of the Literature. [PDF]

, 2017
There has been a conscious effort to address osteoporosis in the aging population. As bisphosphonate and intermittent parathyroid hormone (PTH) therapy become more widely prescribed to treat osteoporosis, it is important to understand their effects on ...
Acosta, Frank L, Hah, Raymond, Hsieh, Patrick C, Iorio, Justin A, Jakoi, Andre M, Liu, John C, Patel, Neil N, Pham, Martin H, Stone, Michael A, Wang, Jeffrey C   +9 more
core   +2 more sources

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, EarlyView.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. [PDF]

, 2019
PurposeOsteogenesis imperfecta (OI) predisposes people to recurrent fractures, bone deformities, and short stature. There is a lack of large-scale systematic studies that have investigated growth parameters in OI.MethodsUsing data from the Linked ...
A Lund, A Markmann, AD Letocha, AK Anissipour, Allison Tam, B Sykes, BJ Belt-Niedbala, Brendan Lee, BU Nwosu, C Land, D Gatti, David Cuthbertson, DO Sillence, DR Keene, EL Germain-Lee, ER Barros, F Rauch, F Rauch, FH Glorieux, Francis H. Glorieux, Frank Rauch, I Grafe, Jay R. Shapiro, JC Marini, JC Marini, JD Hald, Jeff Krischer, JM Tanner, K Graff, L Zeitlin, LA Dimeglio, Mahim Jain, Mary Mullins, Melanie Pepin, MG Seikaly, Michael B. Bober, Michaela Durigova, MS Aglan, N Bishop, N Bishop, Peter A. Smith, Peter H. Byers, R Sakkers, RH Engelbert, RH Engelbert, RM Patel, Robert D. Steiner, RT Hamza, S Bellur, Sandesh C. S. Nagamani, Sunil Bellur, T Palomo, T Yang, Tracy Hart, U Vetter, V. Reid Sutton, Y Takeuchi   +56 more
core   +2 more sources